肝移植受者及慢性肝病患者新冠疫苗接种后抗体应答分析
这项前瞻性研究评估了肝移植受者及慢性肝病患者接种新冠疫苗后的抗体应答。在233例患者中,肝移植受者、肝硬化患者和无肝硬化慢性肝病患者在完成疫苗接种后,分别有61.3%和24%出现抗体应答不佳。肝移植、使用≥2种免疫抑制药物及接种单剂强生疫苗与免疫应答不佳相关。
要点
- 肝移植受者接种新冠疫苗后抗体应答不佳比例高达61.3%。
- 慢性肝病患者(伴或不伴肝硬化)抗体应答不佳比例为24%。
- 肝移植、多药免疫抑制及单剂强生疫苗与应答不佳相关。
核心结论
- 肝移植受者和慢性肝病患者接种新冠疫苗后常见抗体应答不佳。
研究设计与样本
- 前瞻性研究,纳入233例患者:62例肝移植受者、79例肝硬化患者(10例失代偿)、92例无肝硬化慢性肝病患者。
- 在完成mRNA疫苗第2剂或强生单剂疫苗接种后4周检测针对刺突蛋白的抗体应答。
主要发现
- 62例肝移植受者中,11例抗体检测不到,27例抗体次优(中位滴度17.6,范围0.47-212 U/ml)。
- 79例肝硬化患者中,3例抗体检测不到,15例抗体次优(中位滴度41.3,范围0.49-221 U/L)。
- 92例无肝硬化慢性肝病患者中,4例抗体检测不到,19例抗体次优(中位滴度95.5,范围4.9-234 U/L)。
- 多因素分析显示,肝移植、使用2种或以上免疫抑制药物以及接种单剂强生疫苗与免疫应答不佳相关。
- 未报告任何严重不良事件。
关键数值与推荐
- 抗体滴度定义:检测不到<0.40 U/ml,次优0.40-250 U/ml,充足>250 U/ml。
- 肝移植受者中61.3%抗体应答不佳(检测不到或次优)。
- 慢性肝病患者(伴或不伴肝硬化)中24%抗体应答不佳。
临床怎么用
- 对肝移植受者及使用多种免疫抑制药物的慢性肝病患者,接种新冠疫苗后应关注抗体应答可能不佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver transplant (LT) recipients or other immunocompromised patients were not included in the registration trials studying the efficacy of vaccines against SARS-CoV-2. Although the clinical efficacy of COVID-19 vaccines in immunocompromised patients is unknown, many societies have recommended vaccination of this highly vulnerable patient population. METHODS: In this prospective study, we determined antibody responses to spike protein, 4 weeks after the 2nd dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine, in LT recipients and those with chronic liver disease (CLD) with and without cirrhosis. RESULTS: Of the 233 patients enrolled so far, 62 were LT recipients, 79 had cirrhosis (10 decompensated) and 92 had CLD without cirrhosis. Antibody titers were defined as undetectable (<0.40 U/ml), suboptimal (0.40-250 U/ml) and adequate (>250 U/ml). Of the 62 patients who had LT, antibody levels were undetectable in 11 patients and suboptimal (median titer 17.6, range 0.47-212 U/ml) in 27 patients. Among 79 patients with cirrhosis, 3 had undetectable antibody levels and 15 had suboptimal (median titer 41.3, range 0.49-221 U/L) antibody responses. Of the 92 patients without cirrhosis, 4 had undetectable antibody levels and 19 had suboptimal (median titer 95.5, range 4.9-234 U/L) antibody responses. Liver transplantation, use of 2 or more immunosuppression medications and vaccination with a single dose of the Johnson & Johnson vaccine were associated with poor immune response on multivariable analysis. No patient had any serious adverse events. CONCLUSIONS: Poor antibody responses after SARS-CoV-2 vaccination were seen in 61% of LT recipients and 24% of those with CLD. LAY SUMMARY: The clinical efficacy of COVID-19 vaccines in immunocompromised patients is unknown. We performed a prospective study to evaluate immune responses to COVID-19 vaccines (Moderna, Pfizer or Johnson & Johnson) in 62 liver transplant recipients, 79 patients with cirrhosis and 92 with chronic liver diseases without cirrhosis. We found that 17.8% of liver transplant recipients, 3.8% of those with cirrhosis and 4.3% of those with chronic liver diseases without cirrhosis had undetectable antibody levels. In total, 61.3% of liver transplant recipients and 24% of those with chronic liver diseases (with or without cirrhosis) had poor antibody responses (undetectable or suboptimal). Liver transplantation, use of immunosuppressive medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor antibody responses when adjusted for other factors.
引用
- Thuluvath PJ, Robarts P, Chauhan M, et al. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021. PMID: 34454993. doi:10.1016/j.jhep.2021.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。